Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 16

1.

Risks and benefits with bevacizumab: evidence and clinical implications.

Kurkjian C, Kim ES.

Ther Adv Drug Saf. 2012 Apr;3(2):59-69. doi: 10.1177/2042098611430109. Review.

PMID:
25083226
[PubMed]
Free PMC Article
2.

Anti-angiogenesis in prostate cancer: knocked down but not out.

Bilusic M, Wong YN.

Asian J Androl. 2014 May-Jun;16(3):372-7. doi: 10.4103/1008-682X.125903.

PMID:
24759579
[PubMed - in process]
Free PMC Article
3.

Combined inhibition of epidermal growth factor receptor and cyclooxygenase-2 leads to greater anti-tumor activity of docetaxel in advanced prostate cancer.

Lin J, Wu H, Shi H, Pan W, Yu H, Zhu J.

PLoS One. 2013 Oct 14;8(10):e76169. doi: 10.1371/journal.pone.0076169. eCollection 2013.

PMID:
24155892
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

The lysine specific demethylase-1 (LSD1/KDM1A) regulates VEGF-A expression in prostate cancer.

Kashyap V, Ahmad S, Nilsson EM, Helczynski L, Kenna S, Persson JL, Gudas LJ, Mongan NP.

Mol Oncol. 2013 Jun;7(3):555-66. doi: 10.1016/j.molonc.2013.01.003. Epub 2013 Jan 19.

PMID:
23384557
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Targeting MET and vascular endothelial growth factor receptor signaling in castration-resistant prostate cancer.

Lee RJ, Smith MR.

Cancer J. 2013 Jan-Feb;19(1):90-8. doi: 10.1097/PPO.0b013e318281e280. Review.

PMID:
23337762
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failures.

Huang X, Chau CH, Figg WD.

J Hematol Oncol. 2012 Jul 2;5:35. doi: 10.1186/1756-8722-5-35. Review.

PMID:
22747660
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Emerging targeted therapies for castration-resistant prostate cancer.

Adamo V, Noto L, Franchina T, Chiofalo G, Picciotto M, Toscano G, Caristi N.

Front Endocrinol (Lausanne). 2012 May 31;3:73. doi: 10.3389/fendo.2012.00073. eCollection 2012.

PMID:
22666217
[PubMed]
Free PMC Article
8.

Effect of angiogenesis inhibitor bevacizumab on survival in patients with cancer: a meta-analysis of the published literature.

Su Y, Yang WB, Li S, Ye ZJ, Shi HZ, Zhou Q.

PLoS One. 2012;7(4):e35629. doi: 10.1371/journal.pone.0035629. Epub 2012 Apr 23.

PMID:
22539986
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Castration-resistant prostate cancer: mechanisms, targets, and treatment.

Amaral TM, Macedo D, Fernandes I, Costa L.

Prostate Cancer. 2012;2012:327253. doi: 10.1155/2012/327253. Epub 2012 Mar 5.

PMID:
22530130
[PubMed]
Free PMC Article
10.

Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.

Kelly WK, Halabi S, Carducci M, George D, Mahoney JF, Stadler WM, Morris M, Kantoff P, Monk JP, Kaplan E, Vogelzang NJ, Small EJ.

J Clin Oncol. 2012 May 1;30(13):1534-40. doi: 10.1200/JCO.2011.39.4767. Epub 2012 Mar 26.

PMID:
22454414
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Targeting angiogenesis for the treatment of prostate cancer.

Antonarakis ES, Carducci MA.

Expert Opin Ther Targets. 2012 Apr;16(4):365-76. doi: 10.1517/14728222.2012.668887. Epub 2012 Mar 13. Review.

PMID:
22413953
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Changes in biomarkers of inflammation and angiogenesis during androgen deprivation therapy for prostate cancer.

Saylor PJ, Kozak KR, Smith MR, Ancukiewicz MA, Efstathiou JA, Zietman AL, Jain RK, Duda DG.

Oncologist. 2012;17(2):212-9. doi: 10.1634/theoncologist.2011-0321. Epub 2012 Feb 2.

PMID:
22302227
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Emerging novel therapies for advanced prostate cancer.

Osanto S, Van Poppel H.

Ther Adv Urol. 2012 Feb;4(1):3-12. doi: 10.1177/1756287211432777.

PMID:
22295041
[PubMed]
Free PMC Article
14.

Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial.

Ross RW, Galsky MD, Febbo P, Barry M, Richie JP, Xie W, Fennessy FM, Bhatt RS, Hayes J, Choueiri TK, Tempany CM, Kantoff PW, Taplin ME, Oh WK.

Cancer. 2012 Oct 1;118(19):4777-84. doi: 10.1002/cncr.27416. Epub 2012 Jan 26.

PMID:
22282219
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Progress of molecular targeted therapies for prostate cancers.

Fu W, Madan E, Yee M, Zhang H.

Biochim Biophys Acta. 2012 Apr;1825(2):140-52. doi: 10.1016/j.bbcan.2011.11.003. Epub 2011 Nov 29. Review.

PMID:
22146293
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Current treatment strategies for castration-resistant prostate cancer.

Kim SJ, Kim SI.

Korean J Urol. 2011 Mar;52(3):157-65. doi: 10.4111/kju.2011.52.3.157. Epub 2011 Mar 18.

PMID:
21461278
[PubMed]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk